Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCURGet Rating) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 2,330,000 shares, a decrease of 29.2% from the April 15th total of 3,290,000 shares. Based on an average trading volume of 10,860,000 shares, the days-to-cover ratio is currently 0.2 days.

XCUR opened at $0.12 on Friday. The stock has a market cap of $15.10 million, a PE ratio of -0.17 and a beta of 1.60. Exicure has a 52 week low of $0.10 and a 52 week high of $1.98. The business’s fifty day simple moving average is $0.19 and its 200 day simple moving average is $0.32.

Exicure (NASDAQ:XCURGet Rating) last released its earnings results on Friday, March 25th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. The firm had revenue of $2.12 million during the quarter. As a group, equities research analysts predict that Exicure will post -0.15 EPS for the current year.

Several large investors have recently made changes to their positions in the company. Morgan Stanley grew its stake in shares of Exicure by 34.8% during the second quarter. Morgan Stanley now owns 49,425 shares of the company’s stock valued at $74,000 after buying an additional 12,751 shares during the last quarter. Raymond James & Associates grew its stake in shares of Exicure by 20.8% during the third quarter. Raymond James & Associates now owns 75,500 shares of the company’s stock valued at $91,000 after buying an additional 13,000 shares during the last quarter. UBS Group AG grew its stake in shares of Exicure by 184.9% during the third quarter. UBS Group AG now owns 29,409 shares of the company’s stock valued at $35,000 after buying an additional 19,087 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Exicure by 48.0% during the third quarter. HighTower Advisors LLC now owns 73,867 shares of the company’s stock valued at $88,000 after buying an additional 23,952 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Exicure by 37.0% during the third quarter. BlackRock Inc. now owns 511,345 shares of the company’s stock valued at $614,000 after buying an additional 138,050 shares during the last quarter. 41.68% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research cut Exicure from a “buy” rating to a “hold” rating in a research note on Thursday.

About Exicure (Get Rating)

Exicure, Inc, a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen SA to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.

Further Reading

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.